Latigo Biotherapeutics conducted a randomized Phase 2 trial enrolling 343 patients who underwent tummy tuck surgery. Study participants were assigned to one of four arms: a high dose of the company’s oral investigational drug LTG-001, a low dose of LTG-001, placebo, or a combination of acetaminophen and the opioid hydrocodone. All groups had the option to use the opioid oxycodone as rescue medication if additional analgesia was needed.
The source did not provide numeric dose levels, randomization ratios, primary endpoint definitions beyond the 48-hour assessment, statistical values, or the timing of dosing relative to surgery. Those methodological details and comprehensive trial data were not reported in the article.
According to the report, both LTG-001 dose groups showed statistically significant pain relief compared with placebo at 48 hours after surgery. The article did not include effect sizes, confidence intervals, or p-values, nor did it report detailed pain score trajectories beyond the 48-hour time point.
The trial allowed oxycodone as rescue therapy for patients who required additional analgesia. The report states that participants randomized to the high dose of LTG-001 were significantly less likely to use rescue oxycodone than those randomized to placebo. The source did not provide the absolute or relative reduction in rescue-opioid use, nor the number-needed-to-treat or other measures of clinical impact.
Latigo described LTG-001 as generally safe and well tolerated in this Phase 2 population. The overall rate of adverse events was reportedly higher in the placebo group than in either LTG-001 treatment group. However, several specific adverse events were more common among patients receiving LTG-001:
Beyond these observations, the article did not provide a comprehensive safety table, details on serious adverse events, discontinuations due to adverse events, laboratory or vital-sign findings, or longer-term safety follow-up.
The article frames Latigo’s result as part of a rapidly evolving effort to develop non-opioid pain therapeutics after decades of setbacks in the field. Latigo’s LTG-001 is presented as a potential rival to an existing Vertex pain medicine, Journavx, which is already on the market. The source positions the space as a competitive, multibillion-dollar market opportunity for companies that can demonstrate effective, opioid-sparing analgesia.
The report did not compare LTG-001 and Journavx head-to-head on efficacy, safety, mechanism of action, dosing, or regulatory status. Any mechanistic claims, comparative effectiveness, or commercial projections beyond noting the competitive landscape were not provided in the source text.
The source article summarized topline results from Latigo but omitted many trial specifics that clinicians, reviewers, and regulators would need to assess the data fully. Not reported in the article were:
Those omissions limit the degree to which the trial’s clinical implications can be independently evaluated from the material provided.
Latigo reports that oral LTG-001 produced statistically significant pain relief at 48 hours after tummy tuck surgery compared with placebo and reduced the need for rescue oxycodone in the high-dose group. Safety signals included a higher incidence of fever and lightheadedness in the high-dose arm relative to placebo, though the overall adverse event rate was reported as higher in placebo. The article did not supply comprehensive methodological, efficacy magnitude, or complete safety data; those details were not reported in the source.
This Phase 2 announcement positions LTG-001 as a potential entrant in the expanding market for non-opioid postoperative analgesics and as a possible competitor to Vertex’s Journavx, but fuller data disclosure will be required to evaluate comparative benefit and risk.